News

Dr. Reddy’s launches wearable migraine management device in Europe

The company is introducing Nerivio as part of its strategic expansion into the realm of digital therapeutics in Europe.

• By PharmaNews Live Desk
• Hyderabad
• Apr 11, 2024

News

Dr. Reddy's Laboratories, on Wednesday, unveiled its drug-free migraine management device, Nerivio, in Germany. Through its subsidiary betapharm, the company is introducing Nerivio as part of its strategic expansion into the realm of digital therapeutics in Europe.

Nerivio, a non-invasive solution for migraine relief, has received approval from both the United States Food and Drug Administration (USFDA) and CE marking certification in Europe.

The debut of Nerivio took place in 2023 at the DGN Kongress organized by the German Association of Neurology in Berlin and the 17th European Headache Congress held in Barcelona, Spain. 

Dr. Reddy's is preparing to launch Nerivio at the upcoming Neurological Association of South Africa annual congress on April 17, 2024. Dr. Stewart Tepper, a well-known figure in neurology, and Vice President of the New England Institute for Neurology and Headache, is expected to be present at the event, according to the news reports. 

Following this launch, Nerivio is scheduled to be showcased at the International Headache Society 2024 iHEAD meeting in Berlin in May 2024. Subsequent launches are planned for Spain and the UK.

“At a time when conversations on migraine focus on various challenges such as its impact on women's health, managing migraine during the child-bearing age, and distinguishing migraine from headache, we are pleased to introduce Nerivio to patients in our identified markets”, said  M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy's. 

In India, Nerivio was launched in 2023. The device is supported by Dr. Reddy’s patient support programme called ‘M-Free’.

The ‘M-Free’ program includes a range of services such as patient onboarding, counseling, device demonstrations, doorstep delivery, flexible payment options, informational content, and customer care service. 

“Nerivio has had an encouraging start in India, with recommendation from neurologists in India and bringing relief to patients living with migraine. We believe this product meets a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine”, said Ramana. 

Last year, the company entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company, for the marketing and distribution of Nerivio across various markets.

Migraine poses a significant global health challenge, affecting approximately 30% of adults on 15 or more days per month, with a prevalence ranging from 1.7% to 4% of the population. The latest estimates suggest a global migraine prevalence of 14–15%. In India, round 213 million people suffer from migraine, with women comprising 60% of affected individuals.